# Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.

> **NCT00748709** · PHASE2 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 20 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** BIBW 2992 (Afatinib)

## Key facts

- **NCT ID:** NCT00748709
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-10-01
- **Primary completion:** 2010-11-01
- **Final completion:** —
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00748709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00748709, "Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00748709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*